{
  "Disease": [
    {"role": "user", "content": "Please identify the \"Disease\" entities in the following paragraph. Please present the valid entities as a Markdown table with one column \"Disease\". Make sure to present the entities precisely in the same words as in the original paragraph.\n\nParagraph: Instead , oral administration of S - 1 ( a derivative of 5 - FU ) , at 200 mg / day twice a week , was instituted , because S - 1 has a strong inhibitory effect on dihydropyrimidine dehydrogenase , which catalyzes the degradative of 5 - FU into FBAL .\n\nLet's think step by step."},
    {"role": "assistant", "content": "| Disease |\n| --- |\n| dihydropyrimidine dehydrogenase deficiency |\n\nExplanation:\n\nThe only disease entity mentioned in the paragraph is \"dihydropyrimidine dehydrogenase.\" This enzyme is responsible for the degradation of 5-FU (5-fluorouracil) into FBAL (fluoro-beta-alanine). However, the text mentions that S-1 has a strong inhibitory effect on this enzyme, which implies that the patient may have dihydropyrimidine dehydrogenase deficiency. Therefore, I have included this disease in the table."},
    {"role": "user", "content": "Please remove entities that do not clearly refer to \"Disease\" and present the valid entities as a Markdown table with one column \"Disease\".\n\nMake sure to present the entities precisely in the same words as in the original paragraph."},
    {"role": "assistant", "content": "| Disease |\n| --- |\n| dihydropyrimidine dehydrogenase deficiency |\n\nExplanation:\n\nThe only disease entity mentioned in the paragraph is \"dihydropyrimidine dehydrogenase.\" This enzyme is responsible for the degradation of 5-FU (5-fluorouracil) into FBAL (fluoro-beta-alanine). The text mentions that S-1 has a strong inhibitory effect on this enzyme, which implies that the patient may have dihydropyrimidine dehydrogenase deficiency. Therefore, I have included this disease in the table.\n\nThe other entities mentioned in the paragraph, such as \"oral administration,\" \"S-1,\" \"5-FU,\" \"FBAL,\" and \"twice a week,\" do not clearly refer to diseases, so I have not included them in the table."}
  ],
  "Chemical": [
    {"role": "user", "content": "Please identify the \"Chemical\" entities in the following paragraph. Please present the valid entities as a Markdown table with one column \"Chemical\". Make sure to present the entities precisely in the same words as in the original paragraph.\n\nParagraph: Instead , oral administration of S - 1 ( a derivative of 5 - FU ) , at 200 mg / day twice a week , was instituted , because S - 1 has a strong inhibitory effect on dihydropyrimidine dehydrogenase , which catalyzes the degradative of 5 - FU into FBAL .\n\nLet's think step by step."},
    {"role": "assistant", "content": "| Chemical |\n| --- |\n| S - 1 |\n| 5 - FU |\n| dihydropyrimidine dehydrogenase |\n| FBAL |\n\nExplanation:\n\n1. S - 1: It is a derivative of 5 - FU, mentioned in the paragraph.\n2. 5 - FU: It is a compound and derivative of which S - 1 is made.\n3. dihydropyrimidine dehydrogenase: It is an enzyme that catalyzes the degradative of 5 - FU into FBAL.\n4. FBAL: It is the product of the degradative of 5 - FU, catalyzed by dihydropyrimidine dehydrogenase."},
    {"role": "user", "content": "Please remove entities that do not clearly refer to \"Chemical\" and present the valid entities as a Markdown table with one column \"Chemical\".\n\nMake sure to present the entities precisely in the same words as in the original paragraph."},
    {"role": "assistant", "content": "| Chemical |\n| --- |\n| S - 1 |\n| 5 - FU |\n| FBAL |\n\nExplanation:\n\n1. S - 1: It is a derivative of 5 - FU, mentioned in the paragraph.\n2. 5 - FU: It is a compound and derivative of which S - 1 is made.\n3. FBAL: It is the product of the degradative of 5 - FU, catalyzed by dihydropyrimidine dehydrogenase.\n\nDihydropyrimidine dehydrogenase is not included in the list as it is an enzyme, not a chemical."}
  ]
}